Nifedipine versus atosiban in the treatment of threatened preterm labour (Assessment of Perinatal Outcome after Specific Tocolysis in Early Labour: APOSTEL III-Trial)

Elvira O. G. van Vliet; Ewoud Schuit; Karst Y. Heida; Brent C. Opmeer; Marjolein Kok; Wilfried Gyselaers; Martina M. Porath; Mallory Woiski; Caroline J. Bax; Kitty W. M. Bloemenkamp; Hubertina C. J. Scheepers; Yves Jaquemyn; Erik van Beek; Hans J. J. Duvekot; Maureen T. M. Franssen; Bas N. Bijvank; Joke H. Kok; Arie Franx; Ben Willem J. Mol; Martijn A. Oudijk

doi:10.1186/1471-2393-14-93

Nifedipine versus atosiban in the treatment of threatened preterm labour (Assessment of Perinatal Outcome after Specific Tocolysis in Early Labour: APOSTEL III-Trial)

Elvira O. G. van Vliet^*, Ewoud Schuit, Karst Y. Heida, Brent C. Opmeer, Marjolein Kok, Wilfried Gyselaers, Martina M. Porath, Mallory Woiski, Caroline J. Bax, Kitty W. M. Bloemenkamp, Hubertina C. J. Scheepers, Yves Jaquemyn, Erik van Beek, Hans J. J. Duvekot, Maureen T. M. Franssen, Bas N. Bijvank, Joke H. Kok, Arie Franx, Ben Willem J. Mol, Martijn A. Oudijk

^*Corresponding author for this work

GROW - Reproductive and Perinatal Medicine

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background: Preterm birth is the most common cause of neonatal morbidity and mortality. Postponing delivery for 48 hours with tocolytics to allow for maternal steroid administration and antenatal transportation to a centre with neonatal intensive care unit facilities is the standard treatment for women with threatening preterm delivery in most centres. However, there is controversy as to which tocolytic agent is the drug of first choice. Previous trials have focused on tocolytic efficacy and side effects, and are probably underpowered to detect clinically meaningfull differences in neonatal outcome. Thus, the current evidence is inconclusive to support a balanced recommendation for clinical practice. This multicenter randomised clinical trial aims to compare nifedipine and atosiban in terms of neonatal outcome, duration of pregnancy and maternal side effects. Methods/Design: The Apostel III trial is a nationwide multicenter randomised controlled study. Women with threatened preterm labour (gestational age 25-34 weeks) defined as at least 3 contractions per 30 minutes, and 1) a cervical length of

Original language	English
Article number	93
Journal	BMC Pregnancy and Childbirth
Volume	14
Issue number	1
DOIs	https://doi.org/10.1186/1471-2393-14-93
Publication status	Published - 3 Mar 2014

Keywords

Preterm birth
Tocolytics
Nifedipine
Atosiban
Outcome
Drug safety

Access to Document

10.1186/1471-2393-14-93Licence: CC BY

Cite this

van Vliet, E. O. G., Schuit, E., Heida, K. Y., Opmeer, B. C., Kok, M., Gyselaers, W., Porath, M. M., Woiski, M., Bax, C. J., Bloemenkamp, K. W. M., Scheepers, H. C. J., Jaquemyn, Y., van Beek, E., Duvekot, H. J. J., Franssen, M. T. M., Bijvank, B. N., Kok, J. H., Franx, A., Mol, B. W. J., & Oudijk, M. A. (2014). Nifedipine versus atosiban in the treatment of threatened preterm labour (Assessment of Perinatal Outcome after Specific Tocolysis in Early Labour: APOSTEL III-Trial). BMC Pregnancy and Childbirth, 14(1), Article 93. https://doi.org/10.1186/1471-2393-14-93

@article{d5e5d72c09ae4b21b56f83ddf9d20eda,

title = "Nifedipine versus atosiban in the treatment of threatened preterm labour (Assessment of Perinatal Outcome after Specific Tocolysis in Early Labour: APOSTEL III-Trial)",

abstract = "Background: Preterm birth is the most common cause of neonatal morbidity and mortality. Postponing delivery for 48 hours with tocolytics to allow for maternal steroid administration and antenatal transportation to a centre with neonatal intensive care unit facilities is the standard treatment for women with threatening preterm delivery in most centres. However, there is controversy as to which tocolytic agent is the drug of first choice. Previous trials have focused on tocolytic efficacy and side effects, and are probably underpowered to detect clinically meaningfull differences in neonatal outcome. Thus, the current evidence is inconclusive to support a balanced recommendation for clinical practice. This multicenter randomised clinical trial aims to compare nifedipine and atosiban in terms of neonatal outcome, duration of pregnancy and maternal side effects. Methods/Design: The Apostel III trial is a nationwide multicenter randomised controlled study. Women with threatened preterm labour (gestational age 25-34 weeks) defined as at least 3 contractions per 30 minutes, and 1) a cervical length of ",

keywords = "Preterm birth, Tocolytics, Nifedipine, Atosiban, Outcome, Drug safety",

author = "{van Vliet}, {Elvira O. G.} and Ewoud Schuit and Heida, {Karst Y.} and Opmeer, {Brent C.} and Marjolein Kok and Wilfried Gyselaers and Porath, {Martina M.} and Mallory Woiski and Bax, {Caroline J.} and Bloemenkamp, {Kitty W. M.} and Scheepers, {Hubertina C. J.} and Yves Jaquemyn and {van Beek}, Erik and Duvekot, {Hans J. J.} and Franssen, {Maureen T. M.} and Bijvank, {Bas N.} and Kok, {Joke H.} and Arie Franx and Mol, {Ben Willem J.} and Oudijk, {Martijn A.}",

year = "2014",

month = mar,

day = "3",

doi = "10.1186/1471-2393-14-93",

language = "English",

volume = "14",

journal = "BMC Pregnancy and Childbirth",

issn = "1471-2393",

publisher = "BioMed Central Ltd",

number = "1",

}

van Vliet, EOG, Schuit, E, Heida, KY, Opmeer, BC, Kok, M, Gyselaers, W, Porath, MM, Woiski, M, Bax, CJ, Bloemenkamp, KWM, Scheepers, HCJ, Jaquemyn, Y, van Beek, E, Duvekot, HJJ, Franssen, MTM, Bijvank, BN, Kok, JH, Franx, A, Mol, BWJ & Oudijk, MA 2014, 'Nifedipine versus atosiban in the treatment of threatened preterm labour (Assessment of Perinatal Outcome after Specific Tocolysis in Early Labour: APOSTEL III-Trial)', BMC Pregnancy and Childbirth, vol. 14, no. 1, 93. https://doi.org/10.1186/1471-2393-14-93

Nifedipine versus atosiban in the treatment of threatened preterm labour (Assessment of Perinatal Outcome after Specific Tocolysis in Early Labour: APOSTEL III-Trial). / van Vliet, Elvira O. G.; Schuit, Ewoud; Heida, Karst Y. et al.
In: BMC Pregnancy and Childbirth, Vol. 14, No. 1, 93, 03.03.2014.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Nifedipine versus atosiban in the treatment of threatened preterm labour (Assessment of Perinatal Outcome after Specific Tocolysis in Early Labour: APOSTEL III-Trial)

AU - van Vliet, Elvira O. G.

AU - Schuit, Ewoud

AU - Heida, Karst Y.

AU - Opmeer, Brent C.

AU - Kok, Marjolein

AU - Gyselaers, Wilfried

AU - Porath, Martina M.

AU - Woiski, Mallory

AU - Bax, Caroline J.

AU - Bloemenkamp, Kitty W. M.

AU - Scheepers, Hubertina C. J.

AU - Jaquemyn, Yves

AU - van Beek, Erik

AU - Duvekot, Hans J. J.

AU - Franssen, Maureen T. M.

AU - Bijvank, Bas N.

AU - Kok, Joke H.

AU - Franx, Arie

AU - Mol, Ben Willem J.

AU - Oudijk, Martijn A.

PY - 2014/3/3

Y1 - 2014/3/3

N2 - Background: Preterm birth is the most common cause of neonatal morbidity and mortality. Postponing delivery for 48 hours with tocolytics to allow for maternal steroid administration and antenatal transportation to a centre with neonatal intensive care unit facilities is the standard treatment for women with threatening preterm delivery in most centres. However, there is controversy as to which tocolytic agent is the drug of first choice. Previous trials have focused on tocolytic efficacy and side effects, and are probably underpowered to detect clinically meaningfull differences in neonatal outcome. Thus, the current evidence is inconclusive to support a balanced recommendation for clinical practice. This multicenter randomised clinical trial aims to compare nifedipine and atosiban in terms of neonatal outcome, duration of pregnancy and maternal side effects. Methods/Design: The Apostel III trial is a nationwide multicenter randomised controlled study. Women with threatened preterm labour (gestational age 25-34 weeks) defined as at least 3 contractions per 30 minutes, and 1) a cervical length of

AB - Background: Preterm birth is the most common cause of neonatal morbidity and mortality. Postponing delivery for 48 hours with tocolytics to allow for maternal steroid administration and antenatal transportation to a centre with neonatal intensive care unit facilities is the standard treatment for women with threatening preterm delivery in most centres. However, there is controversy as to which tocolytic agent is the drug of first choice. Previous trials have focused on tocolytic efficacy and side effects, and are probably underpowered to detect clinically meaningfull differences in neonatal outcome. Thus, the current evidence is inconclusive to support a balanced recommendation for clinical practice. This multicenter randomised clinical trial aims to compare nifedipine and atosiban in terms of neonatal outcome, duration of pregnancy and maternal side effects. Methods/Design: The Apostel III trial is a nationwide multicenter randomised controlled study. Women with threatened preterm labour (gestational age 25-34 weeks) defined as at least 3 contractions per 30 minutes, and 1) a cervical length of

KW - Preterm birth

KW - Tocolytics

KW - Nifedipine

KW - Atosiban

KW - Outcome

KW - Drug safety

U2 - 10.1186/1471-2393-14-93

DO - 10.1186/1471-2393-14-93

M3 - Article

C2 - 24589124

SN - 1471-2393

VL - 14

JO - BMC Pregnancy and Childbirth

JF - BMC Pregnancy and Childbirth

IS - 1

M1 - 93

ER -

Nifedipine versus atosiban in the treatment of threatened preterm labour (Assessment of Perinatal Outcome after Specific Tocolysis in Early Labour: APOSTEL III-Trial)

Abstract

Keywords

Access to Document

Fingerprint

Cite this